109 related articles for article (PubMed ID: 15848566)
1. Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants.
Bunnapradist S; Takemoto SK
Transplant Proc; 2005 Mar; 37(2):889-91. PubMed ID: 15848566
[TBL] [Abstract][Full Text] [Related]
2. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S
Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574
[TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis of the effectiveness of using antibody induction therapy according to the degree of HLA mismatches.
Bunnapradist S; Hong A; Lee B; Takemoto SK
Transplant Proc; 2005 Mar; 37(2):886-8. PubMed ID: 15848565
[TBL] [Abstract][Full Text] [Related]
4. [Clinical effect of induction therapy with monoclonal antibodies after deceased-donor kidney transplantation (an experience from Vilnius Center)].
Rainiene T; Dobrovolskiene R; Dainys B; Kucinskis G; Zelvys A
Medicina (Kaunas); 2007; 43 Suppl 1():109-13. PubMed ID: 17551287
[TBL] [Abstract][Full Text] [Related]
5. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
[TBL] [Abstract][Full Text] [Related]
6. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome.
Bazerbachi F; Selzner M; Boehnert MU; Marquez MA; Norgate A; McGilvray ID; Schiff J; Cattral MS
Transplantation; 2011 Nov; 92(9):1039-43. PubMed ID: 22002345
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation.
Taber DJ; Weimert NA; Henderson F; Lin A; Bratton CF; Chavin KD; Baliga PK
Transplant Proc; 2008 Dec; 40(10):3401-7. PubMed ID: 19100399
[TBL] [Abstract][Full Text] [Related]
8. Multivariate analyses of antibody induction therapies.
Bunnapradist S; Takemoto SK
Clin Transpl; 2003; ():405-17. PubMed ID: 15387125
[TBL] [Abstract][Full Text] [Related]
9. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
10. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
[TBL] [Abstract][Full Text] [Related]
11. The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study.
Naderi GH; Mehraban D; Ganji MR; Jafarpouriani M; Latif AH
Transplant Proc; 2009 Sep; 41(7):2768-71. PubMed ID: 19765430
[TBL] [Abstract][Full Text] [Related]
12. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
Tan J; Yang S; Wu W
Transplant Proc; 2005 Mar; 37(2):903-5. PubMed ID: 15848570
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab induction in kidney transplantation.
Huang E; Cho YW; Shah T; Peng A; Hayashi R; Bunnapradist S
Clin Transpl; 2005; ():343-54. PubMed ID: 17424750
[TBL] [Abstract][Full Text] [Related]
14. Kidney transplantation, the Halifax experience.
Belitsky P; MacDonald AS; Lawen J; McAlister V; Bitter-Suermann H; Kiberd B; West K; Sketris I
Clin Transpl; 1996; ():231-40. PubMed ID: 9286572
[TBL] [Abstract][Full Text] [Related]
15. Induction therapy in pediatric kidney transplant recipients discharged with a triple drug immunosuppressive regimen.
Sampaio MS; Poommipanit N; Kuo HT; Reddy PN; Cho YW; Shah T; Bunnapradist S
Pediatr Transplant; 2010 Sep; 14(6):770-8. PubMed ID: 20477974
[TBL] [Abstract][Full Text] [Related]
16. Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants.
Campbell SB; Hothersall E; Preston J; Brown AM; Hawley CM; Wall D; Griffin AD; Isbel NM; Nicol DL; Johnson DW
Transplantation; 2003 Nov; 76(10):1452-7. PubMed ID: 14657685
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
18. The UNOS Scientific Renal Transplant Registry--ten years of kidney transplants.
Cecka JM
Clin Transpl; 1997; ():1-14. PubMed ID: 9919387
[TBL] [Abstract][Full Text] [Related]
19. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age.
Patel SJ; Knight RJ; Suki WN; Abdellatif A; Duhart BT; Krauss AG; Mannan S; Nezakatgoo N; Osama Gaber A
Clin Transplant; 2011; 25(3):E250-6. PubMed ID: 21231963
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and outcomes analyses at 36 months of a prospective, randomized, multicenter, trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
Stratta RJ; Alloway RR; Lo A; Hodge EE
Transplant Proc; 2005 Oct; 37(8):3527-30. PubMed ID: 16298650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
